692 reports of this reaction
1.5% of all MIDAZOLAM HYDROCHLORIDE reports
#11 most reported adverse reaction
RESPIRATORY FAILURE is the #11 most commonly reported adverse reaction for MIDAZOLAM HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 692 FDA adverse event reports linking MIDAZOLAM HYDROCHLORIDE to RESPIRATORY FAILURE. This represents approximately 1.5% of all 46,685 adverse event reports for this drug.
Patients taking MIDAZOLAM HYDROCHLORIDE who experience respiratory failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY FAILURE is a less commonly reported adverse event for MIDAZOLAM HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to respiratory failure, the following adverse reactions have been reported for MIDAZOLAM HYDROCHLORIDE:
The following drugs have also been linked to respiratory failure in FDA adverse event reports:
RESPIRATORY FAILURE has been reported as an adverse event in 692 FDA reports for MIDAZOLAM HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY FAILURE accounts for approximately 1.5% of all adverse event reports for MIDAZOLAM HYDROCHLORIDE, making it a notable side effect.
If you experience respiratory failure while taking MIDAZOLAM HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.